Literature DB >> 33205485

ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.

A Wollenberg1, S Christen-Zäch2, A Taieb3, C Paul4, J P Thyssen5, M de Bruin-Weller6, C Vestergaard7, J Seneschal8, T Werfel9, M J Cork10, B Kunz11, R Fölster-Holst12, M Trzeciak13, U Darsow14,15, Z Szalai16, M Deleuran7, L von Kobyletzki17,18, S Barbarot19, A Heratizadeh9, U Gieler20, D J Hijnen21, S Weidinger12, L De Raeve22, Å Svensson23, D Simon24, J F Stalder25, J Ring14,26.   

Abstract

Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis is made using evaluated clinical criteria. Disease activity and burden are best measured with a composite score, assessing both objective and subjective symptoms, such as SCORing Atopic Dermatitis (SCORAD). AD management must take into account clinical and pathogenic variabilities, the patient's age and also target flare prevention. Basic therapy includes hydrating and barrier-stabilizing topical treatment universally applied, as well as avoiding specific and unspecific provocation factors. Visible skin lesions are treated with anti-inflammatory topical agents such as corticosteroids and calcineurin inhibitors (tacrolimus and pimecrolimus), which are preferred in sensitive locations. Topical tacrolimus and some mid-potency corticosteroids are proven agents for proactive therapy, which is defined as the long-term intermittent anti-inflammatory therapy of frequently relapsing skin areas. Systemic anti-inflammatory or immunosuppressive treatment is a rapidly changing field requiring monitoring. Oral corticosteroids have a largely unfavourable benefit-risk ratio. The IL-4R-blocker dupilumab is a safe, effective and licensed, but expensive, treatment option with potential ocular side-effects. Other biologicals targeting key pathways in the atopic immune response, as well as different Janus kinase inhibitors, are among emerging treatment options. Dysbalanced microbial colonization and infection may induce disease exacerbation and can justify additional antimicrobial treatment. Systemic antihistamines (H1R-blockers) only have limited effects on AD-related itch and eczema lesions. Adjuvant therapy includes UV irradiation, preferably narrowband UVB or UVA1. Coal tar may be useful for atopic hand and foot eczema. Dietary recommendations should be patient-specific, and elimination diets should only be advised in case of proven food allergy. Allergen-specific immunotherapy to aeroallergens may be useful in selected cases. Psychosomatic counselling is recommended to address stress-induced exacerbations. Efficacy-proven 'Eczema school' educational programmes and therapeutic patient education are recommended for both children and adults.
© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33205485     DOI: 10.1111/jdv.16892

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  32 in total

1.  Treatment Patterns among Patients with Atopic Dermatitis in Secondary Care: A National, Observational, Non-interventional, Retrospective Study in Sweden.

Authors:  Emma K Johansson; Andreas Brenneche; Dennis Trangbaek; M Natalia Stelmaszuk; Jonatan Freilich; Chris D Anderson
Journal:  Acta Derm Venereol       Date:  2022-09-06       Impact factor: 3.875

2.  Dupilumab Improves Skin Barrier Function in Adults with Atopic Dermatitis: A Prospective Observational Study.

Authors:  Trinidad Montero-Vilchez; Juan-Angel Rodriguez-Pozo; Pablo Diaz-Calvillo; Maria Salazar-Nievas; Jesús Tercedor-Sanchez; Alejandro Molina-Leyva; Salvador Arias-Santiago
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

Review 3.  National Saudi Consensus Statement on the Management of Atopic Dermatitis (2021).

Authors:  Mohammad I Fatani; Afaf A Al Sheikh; Mohammed A Alajlan; Ruaa S Alharithy; Yousef Binamer; Rayan G Albarakati; Khalidah A Alenzi; Amr M Khardaly; Bedor A Alomari; Hajer Y Almudaiheem; Ahmed Al-Jedai; Maysa T Eshmawi
Journal:  Dermatol Ther (Heidelb)       Date:  2022-07-04

4.  Definitions, survey methods, and findings of patient satisfaction studies in teledermatology: a systematic review.

Authors:  Edward Hadeler; Howard Gitlow; Keyvan Nouri
Journal:  Arch Dermatol Res       Date:  2020-07-28       Impact factor: 3.017

5.  Nomenclature and clinical phenotypes of atopic dermatitis.

Authors:  Giampiero Girolomoni; Marjolein de Bruin-Weller; Valeria Aoki; Kenji Kabashima; Mette Deleuran; Luis Puig; Ashish Bansal; Ana B Rossi
Journal:  Ther Adv Chronic Dis       Date:  2021-03-26       Impact factor: 5.091

6.  Different Approaches to Atopic Dermatitis by Allergists, Dermatologists, and Pediatricians.

Authors:  Suzieni Padoin Zuccolo de Bortoli; Herberto José Chong Neto; Nelson Augusto Rosário Filho
Journal:  Dermatol Res Pract       Date:  2021-12-03

Review 7.  Appraisal of Proactive Topical Therapy in Atopic Dermatitis: Pros and Cons.

Authors:  Anne Sofie Frølunde; Jacob Pontoppidan Thyssen; Mette Deleuran; Christian Vestergaard
Journal:  Am J Clin Dermatol       Date:  2021-07-28       Impact factor: 7.403

Review 8.  Chronic Kidney Disease-Associated Itch (CKD-aI) in Children-A Narrative Review.

Authors:  Radomir Reszke; Katarzyna Kiliś-Pstrusińska; Jacek C Szepietowski
Journal:  Toxins (Basel)       Date:  2021-06-29       Impact factor: 4.546

9.  Impact of Water Exposure and Temperature Changes on Skin Barrier Function.

Authors:  Manuel Herrero-Fernandez; Trinidad Montero-Vilchez; Pablo Diaz-Calvillo; Maria Romera-Vilchez; Agustin Buendia-Eisman; Salvador Arias-Santiago
Journal:  J Clin Med       Date:  2022-01-07       Impact factor: 4.241

10.  House Dust Mite Precision Allergy Molecular Diagnosis (PAMD@) in the Th2-prone Atopic Dermatitis Endotype.

Authors:  Ruperto González-Pérez; Paloma Poza-Guedes; Fernando Pineda; Miriam Castillo; Inmaculada Sánchez-Machín
Journal:  Life (Basel)       Date:  2021-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.